Cite
APA Citation
Tan, E., Lim, W., Ahn, M., Ng, Q., Ahn, J. S., Shao‐Weng Tan, D., Sun, J., Han, M., Payumo, F. C., McKee, K., Yin, W., Credi, M., Agarwal, S., Jac, J., & Park, K. (2018). phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical pharmacology in drug development, 7(5), 532–542. http://access.bl.uk/ark:/81055/vdc_100066419803.0x00000d